scispace - formally typeset
E

Elaine F. Reed

Researcher at University of California, Los Angeles

Publications -  295
Citations -  14308

Elaine F. Reed is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Transplantation & Human leukocyte antigen. The author has an hindex of 56, co-authored 263 publications receiving 12433 citations. Previous affiliations of Elaine F. Reed include Papworth Hospital & University of California.

Papers
More filters
Journal ArticleDOI

Malnutrition and immune cell subsets in children undergoing kidney transplantation

TL;DR: Children with obesity have distinct immunophenotypes that may influence the tailoring of immunosuppression, and it is demonstrated that children with obesity had distinct T-and B-cell signatures relative to those with undernutrition and normal nutrition, even when controlling for immunOSuppression.
Book ChapterDOI

Histocompatibility and Immunogenetics Testing in the 21st Century

TL;DR: The application of new state-of-the-art diagnostic tests that inform on the immune status of the transplant recipient has transformed the role of the immunogenetics laboratory from providing tissue-typing and crossmatching services to assessing immunologic risk, donor selection, and presentation of strategies for desensitization and therapeutic intervention.
Journal ArticleDOI

The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies

TL;DR: A retrospective analysis of gender equality practices of FOCIS is performed to identify areas for improvement and make recommendations accordingly, and proposes a number of recommendations that can be used by FocIS to improve gender equality.
Journal ArticleDOI

Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.

TL;DR: It is suggested that dnDSAs and pfDSAs impact short-term rejection rates but do not negatively impact graft survival or histopathological outcomes at 2 years, and periodic protocol post-transplant DSA monitoring may preemptively identify patients who develop dn DSAs who are at a higher risk for rejection.